Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies

Immune checkpoint blockade therapies (ICBs) are a prominent breakthrough in cancer immunotherapy in recent years (named the 2013 “Breakthrough of the Year” by the Science magazine). Thus far, FDA-approved ICBs primarily target immune checkpoints CTLA-4, PD-1, and PD-L1. Notwithstanding their impress...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Genes Dis
Asıl Yazarlar: Shen, Hongxing, Yang, Eddy Shih-Hsin, Conry, Marty, Fiveash, John, Contreras, Carlo, Bonner, James A., Shi, Lewis Zhichang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Chongqing Medical University 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6997608/
https://ncbi.nlm.nih.gov/pubmed/32042863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.gendis.2019.06.006
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller